Barclays PLC Buys 73,127 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Barclays PLC boosted its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 189.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 111,666 shares of the company's stock after purchasing an additional 73,127 shares during the quarter. Barclays PLC owned about 0.11% of ARS Pharmaceuticals worth $1,618,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in shares of ARS Pharmaceuticals by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,234,805 shares of the company's stock valued at $17,909,000 after acquiring an additional 38,927 shares in the last quarter. XTX Topco Ltd bought a new stake in ARS Pharmaceuticals in the third quarter valued at $250,000. Wellington Management Group LLP raised its holdings in shares of ARS Pharmaceuticals by 38.9% during the third quarter. Wellington Management Group LLP now owns 162,335 shares of the company's stock valued at $2,354,000 after purchasing an additional 45,452 shares during the period. Wexford Capital LP bought a new position in shares of ARS Pharmaceuticals during the 3rd quarter worth about $3,601,000. Finally, State Street Corp grew its stake in shares of ARS Pharmaceuticals by 10.4% in the 3rd quarter. State Street Corp now owns 2,049,542 shares of the company's stock valued at $29,718,000 after buying an additional 193,321 shares during the period. 68.16% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on SPRY. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Leerink Partners increased their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an "outperform" rating in a report on Friday, September 20th. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $24.00.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, CFO Kathleen D. Scott sold 12,500 shares of the business's stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $16.00, for a total value of $200,000.00. Following the transaction, the chief financial officer now owns 4,949 shares in the company, valued at $79,184. The trade was a 71.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Brian Dorsey sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.30, for a total value of $307,500.00. Following the completion of the transaction, the chief operating officer now directly owns 6,024 shares of the company's stock, valued at approximately $74,095.20. This represents a 80.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,208,058 shares of company stock worth $18,541,686. Corporate insiders own 40.10% of the company's stock.

ARS Pharmaceuticals Price Performance

Shares of SPRY stock traded down $0.19 during trading hours on Friday, reaching $11.24. The company had a trading volume of 1,354,563 shares, compared to its average volume of 1,292,144. The business has a fifty day simple moving average of $13.03 and a 200-day simple moving average of $12.75. ARS Pharmaceuticals, Inc. has a 12 month low of $5.74 and a 12 month high of $18.51. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -22.04 and a beta of 0.96.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.